A Regional Observational Study on COVID-19-Associated Pulmonary Aspergillosis (CAPA) within Intensive Care Unit: Trying to Break the Mold
Authors:
- Tommaso LupiaTLTommaso Lupia
- Giorgia MontrucchioGMGiorgia Montrucchio
- Alberto GaviraghiAGAlberto Gaviraghi
- Gaia MussoGMGaia Musso
- Mattia PuppoMPMattia Puppo
- Cesare BollaCBCesare Bolla
- Nour ShbakloNour Shbaklo
- Barbara RizzelloBRBarbara Rizzello
- Andrea Della SelvaASAndrea Della Selva
- Erika ConcialdiECErika Concialdi
- Francesca RumboloFRFrancesca Rumbolo
- Anna Maria BarbuiABAnna Maria Barbui
Open Access
- 30 November 2022
- journal article
- research article
- Published by MDPI AG in Journal of Fungi
- Vol. 8 (12) , 1264
Abstract
The reported incidence of COVID-19-associated pulmonary aspergillosis (CAPA) ranges between 2.4% and 35% in intensive care unit (ICU) patients, and awareness in the medical community is rising. We performed a regional retrospective observational study including patients diagnosed with CAPA defined according to the Modified AspICU Dutch/Belgian Mycosis Study Group and CAPA–EECMM, from five different ICUs, admitted between March, 2020 and September, 2021. Forty-five patients were included. The median age was 64 (IQR 60–72), mostly (73%) males. At ICU admission, the median Charlson comorbidity index was 3 (2–5), and the simplified acute physiology score (SAPS)-II score was 42 (31–56). The main underlying diseases were hypertension (46%), diabetes (36%) and pulmonary diseases (15%). CAPA was diagnosed within a median of 17 days (IQR 10–21.75) after symptoms onset and 9 days (IQR 3–11) after ICU admission. The overall 28-day mortality rate was 58%, and at univariate analysis, it was significantly associated with older age (p = 0.009) and SAPS-II score at admission (p = 0.032). The use of immunomodulatory agents, p = 0.061; broad-spectrum antibiotics, p = 0.091; positive culture for Aspergillus on BAL, p = 0.065; and hypertension, p = 0.083, were near reaching statistical significance. None of them were confirmed in multivariate analysis. In critically ill COVID-19 patients, CAPA acquired clinical relevance in terms of incidence and reported mortality. However, the risk between underdiagnosis—in the absence of specific invasive investigations, and with a consequent possible increase in mortality—and over-diagnosis (case identification with galactomannan on broncho-alveolar fluid alone) might be considered. Realistic incidence rates, based on local, real-life epidemiological data, might be helpful in guiding clinicians.Keywords
This publication has 33 references indexed in Scilit:
- Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidanceThe Lancet Infectious Diseases, 2021
- Severe covid-19 pneumonia: pathogenesis and clinical managementBMJ, 2021
- Clinical Features and Co-Infections in Invasive Pulmonary Aspergillosis in Elderly PatientsInfection and Drug Resistance, 2020
- A National Strategy to Diagnose Coronavirus Disease 2019–Associated Invasive Fungal Disease in the Intensive Care UnitClinical Infectious Diseases, 2020
- Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinionIntensive Care Medicine, 2020
- Diagnosing COVID-19-associated pulmonary aspergillosisThe Lancet Microbe, 2020
- Appropriate Treatment of Invasive Candidiasis in ICU: Timing, Colonization Index, Candida Score & Biomarkers, Towards de-Escalation?Turkish Journal of Anesthesia and Reanimation, 2017
- Antifungal Treatment Strategies in the ICU: Beyond Meta-analysisTurkish Journal of Anesthesia and Reanimation, 2017
- A New Simplified Acute Physiology Score (SAPS II) Based on a European/North American Multicenter StudyJAMA, 1993
- A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter studyJAMA, 1993